PRME

$3.71+0.04 (+1.23%)

Market OpenAs of Mar 17, 6:53 PM UTC

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.71
Potential Upside
5%
Whystock Fair Value$3.90
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulom...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$670.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-146.81%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.75

Recent News

Insider Monkey
Mar 8, 2026

Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

Prime Medicine Inc. (NASDAQ:PRME) is one of the best new penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 financial results, highlighting a shift toward its in vivo liver franchise. The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027. Despite […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 3, 2026

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Feb 18, 2026

Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company

Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 11, 2026

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jan 27, 2026

Favourable Signals For Prime Medicine: Numerous Insiders Acquired Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.